The RIG-I/MAVS signaling pathway in cancer cell-selective apoptosis

OncoImmunology

Volumn 2, Issue 4, 2013, Pages

  Kaneda, Yasufumi ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Cancer; HVJ; MAVS; Oncolytic virus; Rig i; Viral RNA

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON; MITOCHONDRIAL ANTIVIRAL SIGNALING PROTEIN; MITOCHONDRIAL PROTEIN; ONCOLYTIC SENDAI VIRUS; ONCOLYTIC VIRUS; PROTEIN BAX; PROTEIN BCL XL; PROTEIN C; PROTEIN NOXA; PUMA PROTEIN; RETINOIC ACID INDUCIBLE PROTEIN I; STAT1 PROTEIN; STAT2 PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VIRUS RNA;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CASTRATION RESISTANT PROSTATE CANCER; CYTOKINE RESPONSE; DNA METHYLATION; GENE; GENE ACTIVATION; GENE EXPRESSION REGULATION; HISTONE MODIFICATION; HUMAN; INFECTION PREVENTION; INNATE IMMUNITY; INTRACELLULAR SIGNALING; LUNG CANCER; MDA5 GENE; MELANOMA; MELANOMA CELL; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROSTATE CANCER; PROTEIN EXPRESSION; SENDAI VIRUS; VIRUS ENVELOPE; VIRUS GENOME; VIRUS REPLICATION;

EID: 84886943336     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.23566     Document Type: Article

References (10)

1. Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther 2007; 15:651-9.
2. Guo ZS, Thorne SH, Bartlett DL. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta 2008; 1785:217-31.
3. Patel B, Dey A, Ghorani E, Kumar S, Malam Y, Rai L, et al. Differential cytopathology and kinetics of measles oncolysis in two primary B-cell malignancies provides mechanistic insights. Mol Ther 2011; 19:1034-40; http://dx.doi.org/10.1038/ mt.2011.44
4. Matsushima-Miyagi T, Hatano K, Nomura M, Li-Wen L, Nishikawa T, Saga K, et al. TRAIL and Noxa are selectively upregulated in prostate cancer cells downstream of the RIG-I/MAVS signaling pathway by nonreplicating Sendai virus particles. Clin Cancer Res 2012; 18:6271-83; http://dx.doi. org/10.1158/1078-0432.CCR-12-1595
5. Yoneyama M, Fujita T. Recognition of viral nucleic acids in innate immunity. Rev Med Virol 2010; 20:4-22; http://dx.doi.org/10.1002/ rmv.633
6. Kurooka M, Kaneda Y. Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Res 2007; 67:227-36; http://dx.doi. org/10.1158/0008-5472.CAN-06-1615
7. Kaneda Y. Virosome: a novel vector to enable multimodal strategies for cancer therapy. Adv Drug Deliv Rev 2012; 64:730-8; http://dx.doi. org/10.1016/j.addr.2011.03.007
8. Besch R, Poeck H, Hohenauer T, Senft D, Häcker G, Berking C, et al. Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferonindependent apoptosis in human melanoma cells. J Clin Invest 2009; 119:2399-411.
9. Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 2011; 11:726-34; http://dx.doi.org/10.1038/nrc3130
10. Kato A, Ohnishi Y, Kohase M, Saito S, Tashiro M, Nagai Y. Y2, the smallest of the Sendai virus C proteins, is fully capable of both counteracting the antiviral action of interferons and inhibiting viral RNA synthesis. J Virol 2001; 75:3802-10; http://dx.doi.org/10.1128/JVI.75.8.3802-3810.2001